Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Source: SeekingAlpha
2026-05-19 22:10:44 ET
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations May 19, 2026 4:30 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Protara Therapeutics Inc.
NASDAQ: TARA
TARA Trading
-2.97% G/L:
$4.25 Last:
156,264 Volume:
$4.43 Open:
TARA Latest News
May 20, 2026 08:00:00 am
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 18, 2026 08:00:00 am
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
May 15, 2026 07:00:00 am
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
May 13, 2026 08:00:00 am
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
TARA Stock Data
$335,599,804
47,293,757
3.64%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
